David S. Perlin, Ph.D
Chief Scientific Officer, Senior Vice President of the Hackensack Meridian Health Center for Discovery and Innovation
Updated: December 20, 2019
David S. Perlin, Ph.D., the chief scientific officer and senior vice president of the Hackensack Meridian Health Center for Discovery and Innovation, received the “Outstanding Scientist” award as part of the 2020 EJI Excellence in Medicine awards.
Dr. Perlin was cited for “his significant accomplishments as a researcher and visionary in the development of innovative therapies to combat antimicrobial resistance,” according to the EJI awards citation, announced by MDAdvantage Insurance Company, a leading provider of medical professional liability insurance.
Dr. Perlin joined the Center for Discovery and Innovation in January 2019. In May, he received a $33.3 million grant from the National Institutes of Health to develop new antibiotics to overcome deadly bacteria in hospitals that have become resistant to current treatments.
In one of his most recent accomplishments, his group explained the molecular mechanisms for drug resistance in Candida auris, a deadly fungal infection that is currently one of the most high-profile emerging threats in health care. Dr. Perlin and his colleagues also developed the first comprehensive rapid diagnostic test for pathogen identification and drug resistance of the fungus. His group has worked closely with the CDC on this epidemic in New York and New Jersey, and other global health departments.
Over a period of about 30 years, Dr. Perlin has been at the forefront of scientific research into antimicrobial drug resistance. He helped develop a number of novel therapeutics and diagnostics, some of which are now commercial products. He also developed a wide range of domestic and global programs addressing both hospital- and community-associated drug resistance. His team of researchers has developed molecular diagnostic products for the CDC and local hospitals for multidrug resistant outbreak pathogens including drug-resistance determinants.
He has worked with numerous device manufacturers and pharmaceutical companies, as well as with the FDA and EMA. He also serves as an advisory board member to numerous pharmaceutical, biotech and diagnostic companies for development of novel therapeutics and diagnostics targeting drug-resistant pathogens.
The EJI Excellence in Medicine awards are considered to be among the highest honors presented to New Jersey’s medical community.